Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinod K Rustgi

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Frontiers in Oncology|July 6, 2019
Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing OutcomesMutlay Sayan, Nikhil Yegya-Raman, Stephanie H Greco, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
The Journal of Clinical Investigation|March 29, 2022
Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse modelStephania Guzman, Magdalena Dragan, Hyokjoon Kwon, et al.
Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
The Lancet. Infectious Diseases|June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trialStanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
Gut|August 1, 2014
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised studyChristophe Hézode, Gideon M Hirschfield, Wayne Ghesquiere, et al.
Gut|March 2, 2026
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statementChu-Tian Wu, Giovanni Targher, Christopher D Byrne, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Frontiers in Oncology|July 6, 2019
Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing OutcomesMutlay Sayan, Nikhil Yegya-Raman, Stephanie H Greco, et al.
Gut|August 30, 2011
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3Alexander J Thompson, Keyur Patel, Wan-Long Chuang, et al.
The Journal of Clinical Investigation|March 29, 2022
Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse modelStephania Guzman, Magdalena Dragan, Hyokjoon Kwon, et al.
Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
The Lancet. Infectious Diseases|June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trialStanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
Gut|August 1, 2014
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised studyChristophe Hézode, Gideon M Hirschfield, Wayne Ghesquiere, et al.
Gut|March 2, 2026
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statementChu-Tian Wu, Giovanni Targher, Christopher D Byrne, et al.
Pageof 8